EP3672569A1 - Bain de bouche contenant du chlorhydrate d'octénidine - Google Patents
Bain de bouche contenant du chlorhydrate d'octénidineInfo
- Publication number
- EP3672569A1 EP3672569A1 EP18755779.8A EP18755779A EP3672569A1 EP 3672569 A1 EP3672569 A1 EP 3672569A1 EP 18755779 A EP18755779 A EP 18755779A EP 3672569 A1 EP3672569 A1 EP 3672569A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- previous
- component
- composition
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000002324 mouth wash Substances 0.000 title claims abstract description 8
- 229940051866 mouthwash Drugs 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 239000000243 solution Substances 0.000 claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 108010011485 Aspartame Proteins 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- 239000000176 sodium gluconate Substances 0.000 claims description 4
- 235000012207 sodium gluconate Nutrition 0.000 claims description 4
- 229940005574 sodium gluconate Drugs 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000007505 plaque formation Effects 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- FUWVMBCPMRAWPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxyoctadecanoate Chemical group CCCCCCCCCCCCCCCCC(O)C(=O)OCC(O)CO FUWVMBCPMRAWPG-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 26
- 238000003860 storage Methods 0.000 description 23
- 239000003995 emulsifying agent Substances 0.000 description 21
- 230000000845 anti-microbial effect Effects 0.000 description 19
- 239000013078 crystal Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 229960001774 octenidine Drugs 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- -1 keto compound Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to an aqueous composition which contains octenidine dihydrochloride .
- the composition is preferably used as a mouthwash or oromucosal solution (solution for use in the oral cavity) , for i) transient germ count reduction in the oral space, ii) inhibition of plaque formation iii) in case of limited oral hygiene capability.
- DE 10 2006 051 891 Al discloses a water-based antimicrobially active composition which contains a bispyridinium alkane (such as octenidine dihydrochloride, also referred to below as "octenidine”) , and the use of the composition as a mouth rinse solution or oral antiseptic.
- octenidine bispyridinium alkane
- compositions given as examples have a pH of 4 and have good activity in the quantitative suspension experiment with E. faecalis (ATCC 19433) and in the quantitative suspension experiment with various MRSA isolates under dirty conditions .
- some formulations in DE 10 2006 051 891 Al contain phenoxyethanol .
- a disadvantage with phenoxyethanol is the furry taste.
- DE 10 2006 051 891 Al For a pleasant taste, in DE 10 2006 051 891 Al it is for example proposed to use aspartame as a sweetener. If one now attempts, starting from this teaching, to further improve the taste or the compositions of DE 10 2006 051 891 Al, for example by increasing the quantity of flavouring used, the quantity of sweetener must also be increased, and, in order to increase the storage stability, also the quantity of emulsifier. However, it has been found than an increased quantity of emulsifier decreases the antimicrobial activity of compositions with a content of octenidine.
- DE 10 2008 011 691 A discloses a stabilized antimicrobially active water-based composition which contains a bispyridinium alkane, and use of the composition for the production of microbicidally active cosmetic and pharmaceutical preparations and for the production of microbicidally equipped articles.
- stabilizers antioxidants, complexing agents, reducing agents, UV filters and light stabilizers are proposed.
- Application solutions described in DE 10 2008 011 691 A contain aspartame as sweetener and in the presence of DL- -tocopherol are storage stable even on storage at 40°C over a period of six months (i.e. no formation of aldehydes or peroxides is observed) .
- DE 10 2005 045 146 A discloses antimicrobial compositions which contain octenidine encapsulated in liposomes.
- DE 196 47 692 A discloses a disinfecting composition which contains octenidine, Ci to Cs alkyl alcohol, nonionic and/or cationic surfactant and skin-compatible a-hydroxycarboxylic acid.
- the present invention was based on the objective of providing aqueous compositions based on the active substance octenidine, which on the one hand are pleasant in taste (i.e. in which the bitter intrinsic taste of octenidine is not apparent) , which however on the other hand contain as few as possible additives which are not necessary for the antimicrobial action and the taste.
- the compositions should nonetheless exhibit very good storage stability.
- gluconic acid or gluconic acid salt in a quantity of 0.2 to 0.6 wt.%, stated as sodium gluconate, e) 0.03 to 0.2 wt.% sucralose, f) citric acid or citric acid salt, in a quantity of 0.05 to 0.15 wt.-%, stated as citric acid (anhydrous) ,
- the composition according to the invention has a pH in the range from 5.0 to 7.0 and contains no aspartame.
- the aqueous composition according to the invention is a clear solution. This solution is characterized by good antimicrobial activity, good storage stability and a pleasant taste.
- the invention thus relates to the aqueous composition.
- the invention relates to use of the aqueous composition as a mouthwash or oromucosal solution.
- the aqueous composition according to the invention according to the first aspect contains
- gluconic acid or gluconic acid salt in a quantity of 0.2 to 0.6 wt.%, stated as sodium gluconate, e) 0.03 to 0.2 wt.% sucralose,
- citric acid or citric acid salt in a quantity of 0.05 to 0.15 wt.%, stated as citric acid (anhydrous) ,
- the quantity of component a) is preferably 0.08 to 0.12 wt.%, more preferably 0.09 to 0.11 wt.%, in particular about 0.1 wt . % .
- the quantity of component b) is preferably 1.5 to 2.0 wt . ⁇ 6 , in particular about 1.75 wt.%.
- the fatty acid monoglyceride substituted with 20 to 70 alkoxy groups is preferably fatty acid monoglyceride substituted with 20 to 70 ethoxy groups, in particular glycerol hydroxystearate substituted with 40 ethylene oxide units.
- the quantity of component c) is preferably 0.35 to 0.5 wt.%, more preferably 0.4 to 0.45 wt.%, in particular about 0.425 wt.%.
- the quantity of component d) is preferably 0.3 to 0.5 wt.%, more preferably 0.35 to 0.45 wt.%, in particular about 0.4 wt . % .
- the quantity of component e) is preferably 0.05 to 0.15 wt.%, more preferably 0.07 to 0.13 wt.%, in particular about 0.1 wt . % .
- the quantity of component f) is preferably 0.07 to 0.11 wt.%, 0.08 to 0.1 wt.%, in particular about 0.09 wt.%.
- the quantity of component g) is preferably 0.1 to 1.0 wt.%, more preferably 0.2 to 0.8 wt.-%, in particular about 0.5 wt.%.
- flavouring g) is preferably selected from
- the buffer h) is preferably a phosphate buffer.
- the composition contains less than 1 wt . % phenoxyethanol , more preferably less than 1 wt . % aromatic alcohol, in particular less than 0.5 wt . % aromatic alcohol, with the composition particularly preferably being free from aromatic alcohol. More preferably the composition contains no tocopherol and no derivative thereof, wherein the composition in particular contains no tocopherol, no derivative thereof and no BHT (butylhydroxytoluene) .
- compositions according to the invention are free from alpha-tocopherol , BHT, tocopherol acetate, BHA (butyl- hydroxyanisole) , dodecyl gallate or ascorbic acid, and preferably contain none of these components.
- the composition according to the invention is preferably used as a mouthwash or oromucosal solution for i) transient microbial count reduction in the oral space, ii) inhibition of plaque formation or iii) in case of limited oral hygiene capability .
- Example 2 Storage stability of a formulation with aspartame
- Table 3 Storage stability of a formulation with aspartame
- the data confirm the unsatisfactory storage stability of octenidine-containing formulations with the sweetener aspartame, even when formulated at the pH of about 4 recommended for aspartame for optimal stability.
- Example 3 Storage stability of a formulation without aspartame
- the emulsifier content was studied around the actual value of 1.75% in a bandwidth from 1.0% to 2.0%. These experiments took place at the average octenidine dihydrochloride concentration (0.15%) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017119261.1A DE102017119261A1 (de) | 2017-08-23 | 2017-08-23 | Octenidindihydrochlorid enthaltendes Mundwasser |
PCT/EP2018/071817 WO2019038110A1 (fr) | 2017-08-23 | 2018-08-10 | Bain de bouche contenant du chlorhydrate d'octénidine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3672569A1 true EP3672569A1 (fr) | 2020-07-01 |
Family
ID=63244588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18755779.8A Withdrawn EP3672569A1 (fr) | 2017-08-23 | 2018-08-10 | Bain de bouche contenant du chlorhydrate d'octénidine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3672569A1 (fr) |
AU (1) | AU2018322279A1 (fr) |
DE (1) | DE102017119261A1 (fr) |
SG (1) | SG11202001406WA (fr) |
WO (1) | WO2019038110A1 (fr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL288963A (fr) * | 1962-02-15 | |||
DE19647692C2 (de) | 1996-11-05 | 2002-06-20 | Schuelke & Mayr Gmbh | Waschendes Desinfektionsmittel zur hygienischen und chirurgischen Händedesinfektion |
DE102005045146A1 (de) | 2005-09-15 | 2007-03-29 | Schülke & Mayr GmbH | Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen |
DE102006051891A1 (de) * | 2006-10-31 | 2008-05-08 | Schülke & Mayr GmbH | Antimikrobiell wirksame Zusammensetzung mit einem Gehalt an Bispyridiniumalkan |
DE102008011691A1 (de) | 2008-02-28 | 2009-09-10 | Schülke & Mayr GmbH | Stabilisierte, antimikrobiell wirksame Zusammensetzung mit einem Gehalt an Bispyridiniumalkan |
DE102009049505A1 (de) * | 2009-10-15 | 2011-04-21 | Schülke & Mayr GmbH | Desinfektionsverfahren mit gleichzeitiger Ultraschallbehandlung |
DE102012215511A1 (de) * | 2012-08-31 | 2014-06-12 | Schülke & Mayr GmbH | Verfahren zur Herstellung einer Bispyridiniumalkan enthaltenden halbfesten Zubereitung |
-
2017
- 2017-08-23 DE DE102017119261.1A patent/DE102017119261A1/de active Pending
-
2018
- 2018-08-10 SG SG11202001406WA patent/SG11202001406WA/en unknown
- 2018-08-10 AU AU2018322279A patent/AU2018322279A1/en active Pending
- 2018-08-10 WO PCT/EP2018/071817 patent/WO2019038110A1/fr unknown
- 2018-08-10 EP EP18755779.8A patent/EP3672569A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2019038110A1 (fr) | 2019-02-28 |
AU2018322279A1 (en) | 2020-03-19 |
SG11202001406WA (en) | 2020-03-30 |
DE102017119261A1 (de) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1543830B1 (fr) | Bactericides antiseptiques et cosmetiques, medicaments et produits alimentaires contenant ces bactericides antiseptiques | |
US5874068A (en) | Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts | |
JP6207541B2 (ja) | 口腔用組成物 | |
EP1543829B1 (fr) | Bactericides antiseptiques et cosmetiques, medicaments et produits alimentaires contenant ces bactericides antiseptiques | |
ES2610193T3 (es) | Composición antimicrobianamente eficaz estabilizada con un contenido de alcano de bispiridinio | |
KR20150027312A (ko) | 디쿠아포솔 함유 점안액 | |
JP5359546B2 (ja) | 液体口腔用組成物 | |
JP2009062285A (ja) | 口腔・咽喉疾患用液剤 | |
JP4278322B2 (ja) | 水溶性クロロヘキシジン含有の粉体状、顆粒状又は錠剤状の組成物、該組成物の製造法及びその使用 | |
KR20220058468A (ko) | 알칸디올, 및 카프릴릴글리세릴에터 또는 에틸헥실글리세린을 포함하는 피부 외용제용 보존제 및 이를 포함하는 화장료 조성물 | |
EP2664318B1 (fr) | Compositions ayant une activité antimicrobiènne comprenant un composé de zinc, de l'éther monoalkylé de glycerine et un antioxidant | |
WO2019038110A1 (fr) | Bain de bouche contenant du chlorhydrate d'octénidine | |
US10010071B2 (en) | Liquid concentrate for the protection of compositions to be applied topically, against microbial attack | |
JP2540892B2 (ja) | 口腔用組成物 | |
JP6634284B2 (ja) | 濃縮抗菌剤組成物 | |
JPH10236951A (ja) | プラノプロフェン配合点眼剤 | |
EP0892785B1 (fr) | Solution antimicrobienne de hydantoine substituee par formaldehyde et procede de preparation | |
EP2873321A1 (fr) | Concentré liquide pour l'équipement antimicrobien de produits devant être appliqués topiquement | |
JP2006176416A (ja) | 口腔用組成物 | |
JP6287342B2 (ja) | 歯磨剤組成物、及び歯磨剤組成物におけるアスコルビン酸リン酸エステル又はその塩の安定性向上方法 | |
EP3533330A1 (fr) | Composition comprenant de l'ester d'éthyle d'acide férulique et aryl-alcanol | |
WO2021104643A1 (fr) | Composition d'agent conservateur | |
JPH08268850A (ja) | 口腔用組成物 | |
CN112544620A (zh) | 一种防腐组合物及其制备方法 | |
CN115089504A (zh) | 新的化妆品组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200323 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230627 |